Yazar "Katgi, Nuran" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    Comparison of Alectinib/Crizotinib Data in First-Line Therapy in Patients with Anaplastic Lymphomakinase- Positive Nonsmall Cell Lung Carcinoma with Poor Prognostic Features for Alectinib
    (Aves, 2023) Katgi, Nuran; Cimen, Pinar; Akyol, Murat; Gursoy, Pinar; Aguloglu, Nursin
    OBJECTIVE: Alectinib has a much better central nervous system transmission than crizotinib in patients diagnosed with anaplastic lym-phoma kinase mutation-positive nonsmall cell lung carcinoma. We aimed to investigate alectinib's efficacy in the treatment and its place in the first-line treatment and report our real-life data. MATERIAL AND METHODS: The data of 38 patients who were diagnosed with anaplastic lymphoma kinase-positive nonsmall cell lung carcinoma in our clinic between 2016 and 2021, who did not receive any treatment before were retrospectively analyzed. RESULTS: Of the 19 patients who received alectinib, 14 had multiple, and 6 had pretreatment brain metastases. No newly emerging brain metastases were detected during the treatment period. The progression-free survival of patients was 23.5 & PLUSMN; 4.2 months, and overall survival was 24.6 & PLUSMN; 4.1 months. Progression was observed in 10 (52.6%) patients. Of the 19 patients who received crizotinib, 7 had multiple metastases, and brain metastases were detected in 1 patient before treatment and 6 patients during the treatment period. Progression-free survival of crizotinib patients was 17.1 & PLUSMN; 4.8 months and their overall survival was 26.5 & PLUSMN; 6.1 months. Progression was observed in 17 (89.5%) patients. The second line of alectinib could be given to 8 of these patients. Overall survival after second-line treatment of alectinib was 18.2 & PLUSMN; 7.0 months. Overall survival of the patients who could not receive second-line treatment of alectinib was 4.0 & PLUSMN; 2.0 months. CONCLUSION: The progression rate was lower in alectinib than the crizotinib patients, although there were more patients with multiple metastases and brain metastases in the alectinib arm.
  • Küçük Resim
    Öğe
    The relationship between thyroid transcription factor-1 positivity and epidermal growth factor receptor mutation in lung adenocarcinoma and its prognostic significance
    (Kare Publ, 2023) Katgi, Nuran; Cimen, Pinar; Akyol, Murat; Aguloglu, Nursin
    BACKGROUND AND AIM: Thyroid transcription factor-1 (TTF-1) is a good prognostic factor and is also thought to be associated with driver mutations in lung cancer. This study aimed to evaluate the relationship between TTF-1 expression and prognosis and driver mutations in lung adenocarcinomas.METHODS: We analyzed the data of 307 patients who were diagnosed with lung adenocarci-noma and underwent TTF-1 testing in two centers between January 2018 and January 2021. RESULTS: Of the 307 patients included in the study, 231 were TTF-1 positive, 23 were weakly positive, and 53 were negative. There was no statistically significant relationship between TTF-1 positivity and progression-free survival (PFS) (p=0.492). However, overall survival (OS) was significantly longer in TTF-1 positive patients (p=0.005). Both PFS and OS were sig-nificantly longer in TTF-1 positive patients with multiple metastates (p=0.001, p=0.013). Of the 199 patients who underwent epidermal growth factor receptor (EGFR) mutation analysis, EGFR positivity was detected in 62 of them, and 58 patients were found to be in the TTF-1 positive group (p=0.022). CONCLUSIONS: Thyroid transcription factor-1 positivity in lung adenocarcinomas is a good prognostic factor that often accompanies EGFR positivity.